Industry News
Biotechnology Industry News

Single-asset Equillium buys Bioniz for up to $329M, adding 3 drugs to its pipeline
Single-asset Equillium buys Bioniz for up to $329M, adding 3 drugs to its pipeline klahucik Tue, 02/15/2022 - 14:54
Electra, one of 2 Star biotechs, snags $84M to apply brakes to ‘immune system haywire’
Electra, one of 2 Star biotechs, snags $84M to apply brakes to 'immune system haywire' klahucik Tue, 02/15/2022 - 13:53
Cytokinetics drug fails late-stage trial testing exercise capacity, as FDA considers nod in heart failure
Cytokinetics drug fails late-stage trial testing exercise capacity, as FDA considers nod in heart failure klahucik Tue, 02/15/2022 - 12:59
Biotech pipeline is outpaced by antibacterial resistance, new BIO report says
Biotech pipeline is outpaced by antibacterial resistance, new BIO report says mbayer Tue, 02/15/2022 - 12:18
Merck gets ahead of the Curve, inking oncology and neurology drug discovery deal with emerging British biotech
Merck gets ahead of the Curve, inking oncology and neurology drug discovery deal with emerging British biotech ntaylor Tue, 02/15/2022 - 12:15
UCB, Novartis and more pile into SpliceBio series A, ponying up $57M to tackle a big barrier to gene therapy
UCB, Novartis and more pile into SpliceBio series A, ponying up $57M to tackle a big barrier to gene therapy ntaylor Tue, 02/15/2022 - 12:06
A new SPAC decides to enter murky waters to hunt for biotechs in downsized $75M IPO
A new SPAC decides to enter murky waters to hunt for biotechs in downsized $75M IPO klahucik Tue, 02/15/2022 - 11:22
IQVIA sees 2021 revenues jump 22% led by strong service growth
IQVIA sees 2021 revenues jump 22% led by strong service growth mbayer Tue, 02/15/2022 - 09:58
Larimar kept in limbo as FDA maintains clinical hold on leading candidate
Larimar kept in limbo as FDA maintains clinical hold on leading candidate mbayer Tue, 02/15/2022 - 09:21
Legend’s early-stage CAR-T on FDA hold after single patient dosed
Legend's early-stage CAR-T on FDA hold after single patient dosed aarmstrong Tue, 02/15/2022 - 08:56
Intellia-ONK ink up to $920M pact for 5 CRISPR-edited cancer cell therapies
Intellia-ONK ink up to $920M pact for 5 CRISPR-edited cancer cell therapies klahucik Tue, 02/15/2022 - 08:47
AC Immune’s Janssen-partnered Alzheimer’s vaccine spurs tau-attacking antibodies in early-stage trial
AC Immune's Janssen-partnered Alzheimer's vaccine spurs tau-attacking antibodies in early-stage trial aarmstrong Tue, 02/15/2022 - 08:36
Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end
Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end ntaylor Tue, 02/15/2022 - 07:57
2seventy bio plucks Turnstone Biologics exec Bernstein to be new CMO
2seventy bio plucks Turnstone Biologics exec Bernstein to be new CMO mbayer Mon, 02/14/2022 - 10:27
Kallyope, with ex-Merck exec at helm, skirts ‘less desirable’ public markets with $236M series D
Kallyope, with ex-Merck exec at helm, skirts 'less desirable' public markets with $236M series D klahucik Mon, 02/14/2022 - 10:25
Improving RNA editing for genetic diseases by recruiting the body’s natural protein
Improving RNA editing for genetic diseases by recruiting the body’s natural protein aliu Mon, 02/14/2022 - 09:51
Roivant decants another Vant armed with Eisai blood cancer drug and plans to start phase 1/2 soon
Roivant decants another Vant armed with Eisai blood cancer drug and plans to start phase 1/2 soon ntaylor Mon, 02/14/2022 - 08:35
FDA fingers tox assessment as cause of Denali clinical hold, leaving biotech with a to-do list to regain momentum
FDA fingers tox assessment as cause of Denali clinical hold, leaving biotech with a to-do list to regain momentum ntaylor Mon, 02/14/2022 - 07:51
Editor’s Corner: Fierce Biotech gets a fierce makeover
Editor's Corner: Fierce Biotech gets a fierce makeover aarmstrong Fri, 02/11/2022 - 15:14
Roche, Lilly push back against CMS painting their Alzheimer’s meds with the same brush as Biogen’s Aduhelm
Roche, Lilly push back against CMS painting their Alzheimer’s meds with the same brush as Biogen’s Aduhelm aarmstrong Fri, 02/11/2022 - 12:40

